Konica Minolta Healthcare Americas partnered with RegenLab USA Feb. 19 to distribute its regenerative medicine portfolio for the orthopedic market in the U.S. and Canada.
Konica's bio-injectable products include preparation devices for platelet-rich plasma and other blood cell therapies, administered using ultrasound guidance.
The single use kits prepare PRP and other cell-based therapies so clinicians can deliver efficiently in their practice.
The regenerative medicine market for sports medicine, orthopedics and pain management is projected to surpass $300 million in North America by 2025, according to a recent report by Grand View Research.